ClinicalTrials.gg
CompletedNCT00002662Updated Aug 2, 2013

Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer

A Phase 3 interventional study of docetaxel and paclitaxel in Breast Cancer, sponsored by Aventis Pharmaceuticals. Completed at 32 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-02.

Sponsored by Aventis Pharmaceuticals (part of Sanofi) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Started
1994
the only one that year
Phase 3
51 of 264
5 open now
Registered
1st of 264
by date

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the only one that started in 1994, is one of 51 in phase 3, and was the 1st registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel is more effective than docetaxel for breast cancer.

PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel or docetaxel in treating women with stage IIIB or metastatic breast cancer.

Read the detailed description

OBJECTIVES:

  • Compare the response rate in women with metastatic or locally advanced, inoperable adenocarcinoma of the breast treated with docetaxel vs paclitaxel.
  • Compare the toxicity of these regimens in these patients.
  • Compare the time to disease progression, duration of response, quality of life, and survival of patients treated with these regimens.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive paclitaxel IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and after courses 4 and 6.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 400 patients (200 per arm) will be accrued for this study.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • stage IV breast cancer
  • stage IIIA breast cancer
  • recurrent breast cancer
  • stage IIIB breast cancer
  • stage IIIC breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • proven or locally advanced, inoperable adenocarcinoma of the breast

    • Clinically evident metastases (e.g., clearly malignant lesions on chest x-ray or CT or abdominal CT do not require histologic confirmation)
    • Hot spots on bone scan not shown to be malignant on plain x-rays are not adequate evidence of malignant disease in the absence of other lesions
  • Must meet 1 of the following conditions:

    • Disease progression after 1 prior chemotherapy regimen for locally advanced or metastatic disease (which may or may not have followed a separate regimen using chemotherapy or hormonal therapy)
    • Locally advanced or metastatic disease during or after 1 adjuvant or neoadjuvant chemotherapy regimen
    • One of the above chemotherapy regimens must have contained an anthracycline (e.g., doxorubicin, but not mitoxantrone)
    • Single drug substitution (e.g., methotrexate for doxorubicin) during prior combination chemotherapy allowed
  • Bidimensionally measurable
  • No clinical or radiographic evidence of brain or
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Sex:

  • Female

Menopausal status:

  • Not specified

Performance status:

  • 60-100% OR
  • 0-2

:

  • At least 12 weeks

Hematopoietic:

  • at least 2,000/mm3
  • count at least 100,000/mm3

Hepatic:

  • normal
  • no greater than 2.5 times

Renal:

  • Creatinine no greater than 2.0 mg/dL
  • No uncontrolled hypercalcemia

Cardiovascular:

  • No myocardial infarction within the past 6 months
  • No history of arrhythmia requiring treatment
  • No heart block
  • No clinical evidence of congestive heart failure
  • No unstable angina (e.g., new onset, crescendo, or rest angina)
  • Stable exertional angina allowed

Other:

  • No current symptomatic grade 2 or greater peripheral neuropathy
  • No history of to products containing Cremophor EL (e.g., cyclosporine or teniposide) or Polysorbate 80 (e.g., IV etoposide)
  • No serious infection
  • No significant psychiatric disease that would preclude study
  • No other within the past 5 years except nonmelanomatous skin cancer or completely excised carcinoma in situ of the cervix
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior bone marrow or stem cell transplantation

Chemotherapy:

  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy (2 weeks for oral cyclophosphamide or 6 weeks for nitrosoureas or mitomycin)
  • No prior high-dose chemotherapy given with ablative intent
  • No prior taxoids
  • No other concurrent antineoplastic therapy

Endocrine therapy:

  • See Disease Characteristics
  • Prior hormonal therapy as adjuvant therapy or for metastatic disease allowed
  • At least 1 week since prior hormonal therapy
  • No concurrent except:

    • Prophylaxis or treatment for acute hypersensitivity reactions
    • Chronic therapy (more than 6 months) at low doses (20 mg/day or less of methylprednisolone or equivalent)

Radiotherapy:

  • At least 4 weeks since prior radiotherapy to major bone marrow areas
  • No prior high-dose radiotherapy given with ablative intent
  • No concurrent radiotherapy except limited palliative radiotherapy (e.g., for a solitary rib fracture) during objective response

Surgery:

  • See Disease Characteristics
  • More than 2 weeks since prior surgery except simple or placement of venous access device

Other:

  • At least 4 weeks since prior drugs
  • Concurrent medications known to alter cardiac conduction (e.g., digoxin, beta blockers, or calcium channel blockers) allowed
  • No concurrent ketoconazole
  • No concurrent bisphosphonates unless initiated more than 3 months before randomization
  • No concurrent experimental drug or therapy
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Masking
None (open label)

Interventions

06

Study locations

32 sites
  • Montclair Regional Cancer Center
    Birmingham, Alabama 35213, United States
  • Highlands Oncology Group, P.A. - Fayetteville
    Fayetteville, Arkansas 72703, United States
  • Northeast Arkansas Clinic
    Jonesboro, Arkansas 72401-3125, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • California Cancer Care, Inc.
    Greenbrae, California 94904-2007, United States
  • Green Cancer Center at Scripps Clinic
    La Jolla, California 92037, United States
  • Sidney Kimmel Cancer Center
    San Diego, California 92121, United States
  • University of Colorado Cancer Center at University of Colorado Health Sciences Center
    Denver, Colorado 80010, United States
  • Norwich Cancer Center
    Norwich, Connecticut 06360, United States
  • George Washington University Medical Center
    Washington, District of Columbia 20037, United States
  • Baptist Regional Cancer Institute - Jacksonville
    Jacksonville, Florida 32207-8554, United States
  • Georgia Cancer Specialists - DeKalb
    Decatur, Georgia 30033, United States
  • Rush-Presbyterian-St. Luke's Medical Center
    Chicago, Illinois 60612, United States
  • James Graham Brown Cancer Center at University of Louisville
    Louisville, Kentucky 40202, United States
  • Maine Center for Cancer Medicine and Blood Disorders - Scarborough
    Scarborough, Maine 04074, United States
  • Tufts - New England Medical Center
    Boston, Massachusetts 02111, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109-0942, United States
  • Southfield Oncology Institute, Inc.
    Southfield, Michigan 48076-3779, United States
  • Mercy Arch Hematology Oncology, P.C.
    Saint Louis, Missouri 63141, United States
  • Carolinas Hematology-Oncology Associates
    Charlotte, North Carolina 28203, United States
  • Blumenthal Cancer Center at Carolinas Medical Center
    Charlotte, North Carolina 28232-2861, United States
  • Charles M. Barrett Cancer Center at University Hospital
    Cincinnati, Ohio 45267-0501, United States
  • Cleveland Clinic Taussig Cancer Center
    Cleveland, Ohio 44195, United States
  • Hematology Oncology Consultants Inc
    Columbus, Ohio 43235, United States
  • Penn State Cancer Institute at Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033-0850, United States
  • Oncology-Hematology Associates
    Philadelphia, Pennsylvania 19107, United States
  • Roger Williams Medical Center
    Providence, Rhode Island 02908-4735, United States
  • Greenville Hospital System
    Greenville, South Carolina 29605, United States
  • Baptist Regional Cancer Center - Knoxville
    Knoxville, Tennessee 37901, United States
  • Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78284-7811, United States
  • Medical College of Wisconsin Cancer Center
    Milwaukee, Wisconsin 53226-3596, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 1994 and a completion of Jun 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 1999
First posted
Jan 27, 2003
Start
Aug 1994
CompletionActual
Jun 2004
Last update
Aug 2, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002662
First posted
Jan 27, 2003
Start date
Aug 1994
Completion
Jun 2004
Last update
Aug 2, 2013

Study contacts

Peter M. Ravdin, MD
study chair · The University of Texas Health Science Center at San Antonio
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2004. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Paclitaxel

Start the discussion